Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ifosfamide clinical pharmacokinetics

¹Department of Internal Medicine, Medical University of Lübeck, Germany.

Clinical Pharmacokinetics

|June 1, 1994

Summary

This summary is machine-generated.

Ifosfamide is a prodrug requiring biotransformation for cytotoxicity. Its metabolism yields chloroacetaldehyde, potentially explaining its therapeutic and toxic effects, including CNS toxicity and urotoxicity, which mesna can mitigate.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hybrid active-passive galactic cosmic ray simulator: Experimental implementation and microdosimetric characterization.

Life sciences in space research·2026

Same author

Hybrid active-passive Galactic Cosmic Ray simulator: In-silico design and optimization.

Life sciences in space research·2026

Same author

Fluorescence lymphography in kidney transplantation (FLIKT-study)-real time intraoperative lymphography to avoid lymphocele formation.

Surgical endoscopy·2026

Same author

Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy.

Journal of neurology·2025

Same author

Dutch Workflow for Diagnosis and Treatment of Velopharyngeal Insufficiency in Patients with Cleft Palate-A Survey Study.

The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association·2025

Same author

Dissolved organic matter quantity and quality response of tropical rainforest headwater rivers to the transition from dry to wet season.

Scientific reports·2024

Same journal

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026

Same journal

Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics.

Clinical pharmacokinetics·2026

Same journal

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026

Same journal

Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing.

Clinical pharmacokinetics·2026

Same journal

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Clinical pharmacokinetics·2026

Same journal

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Clinical pharmacokinetics·2026

See all related articles

Area of Science:

Pharmacology
Oncology
Drug Metabolism

Background:

Ifosfamide is an alkylating agent used in chemotherapy.
It is a prodrug requiring metabolic activation to exert its cytotoxic effects.
Ifosfamide is a structural isomer of cyclophosphamide with distinct metabolic pathways.

Purpose of the Study:

To review the metabolism and pharmacokinetics of ifosfamide.
To correlate these properties with its cytostatic efficacy and toxicity.
To understand the role of metabolites in ifosfamide's therapeutic and adverse effects.

Main Methods:

Review of existing literature on ifosfamide metabolism and pharmacokinetics.
Analysis of metabolic pathways, including activation to 4-hydroxy-ifosfamide and chloroacetaldehyde formation.

Related Experiment Videos

Examination of the impact of metabolites on drug efficacy and toxicity.

Main Results:

Ifosfamide metabolism generates both an activated form and chloroacetaldehyde.
Lower levels of activated drug compared to cyclophosphamide may necessitate higher doses.
Chloroacetaldehyde is implicated in CNS toxicity and glutathione depletion, potentially enhancing anti-tumor activity.
Mesna effectively mitigates ifosfamide-induced urotoxicity without compromising efficacy.

Conclusions:

Ifosfamide's unique metabolism influences its efficacy and toxicity profile.
Chloroacetaldehyde plays a dual role in both adverse and therapeutic effects.
Understanding these pharmacokinetic and metabolic properties is crucial for optimizing ifosfamide therapy.
Mesna is a key agent in managing ifosfamide's dose-limiting urotoxicity.